PDF(Pubmed)
Abstract：
UNASSIGNED: This study aimed to assess the clinical importance of various biomarkers, including NLR, CEA, CA199, CA125, CA153, and HE4, through dynamic testing to evaluate the effectiveness of neoadjuvant chemotherapy (NACT) for individuals facing advanced ovarian cancer. This provides valuable information for tailoring treatment plans to individual patients, thereby leading to a more personalized and effective management of individuals facing ovarian cancer.
UNASSIGNED: The levels of NLR, CA125, CA199, CEA, CA153, and HE4 were detected before chemotherapy and after 3 courses of chemotherapy. Patients were categorized into ineffective and effective groups according to the effectiveness of NACT. To evaluate the factors influencing NACT\'s effectiveness in individuals facing advanced ovarian cancer, receiver operating characteristic (ROC) curves, predictive modeling, and multifactorial regression analysis were employed.
UNASSIGNED: In the effective group, the patients\' age, maximum tumor diameter, and CEA and HE4 levels of the patients were significantly higher compared to those in the ineffective group (P <.05). Additionally, the difference in HE4 levels before and after treatment between the effective and ineffective groups was statistically significant (P<.05). Multifactorial analysis showed that age and maximum tumor diameter were independent risk factors impacting the effectiveness of NACT in individuals facing advanced ovarian cancer (P<.05). The ROC curve for predicting the effectiveness of NACT in individuals facing advanced ovarian cancer showed a sensitivity of 93.3% for NLR and a specificity of 92.3% for CA199. HE4 emerged as the most reliable predictor, demonstrating a specificity of 84.6% and a sensitivity of 75.3%. The area under the curve of the combined CA125 and HE4 assays for predicting the ineffectiveness of NACT in individuals facing advanced ovarian cancer was 0.825, showcasing a specificity of 74.2% and a sensitivity of 84.6%.
UNASSIGNED: The predictive capacity for the effectiveness of NACT in individuals facing advanced ovarian cancer is notably high when considering the sensitivity of NLR and the specificity of CA199. Additionally, the combination of CA125 and HE4 assays can obtain a better predictive effect, which can accurately select patients suitable for NACT, determine the appropriate timing of the interval debulking surgery (IDS) surgery, and achieve a satisfactory tumor reduction effect.
UNASSIGNED: The levels of NLR, CA125, CA199, CEA, CA153, and HE4 were detected before chemotherapy and after 3 courses of chemotherapy. Patients were categorized into ineffective and effective groups according to the effectiveness of NACT. To evaluate the factors influencing NACT\'s effectiveness in individuals facing advanced ovarian cancer, receiver operating characteristic (ROC) curves, predictive modeling, and multifactorial regression analysis were employed.
UNASSIGNED: In the effective group, the patients\' age, maximum tumor diameter, and CEA and HE4 levels of the patients were significantly higher compared to those in the ineffective group (P <.05). Additionally, the difference in HE4 levels before and after treatment between the effective and ineffective groups was statistically significant (P<.05). Multifactorial analysis showed that age and maximum tumor diameter were independent risk factors impacting the effectiveness of NACT in individuals facing advanced ovarian cancer (P<.05). The ROC curve for predicting the effectiveness of NACT in individuals facing advanced ovarian cancer showed a sensitivity of 93.3% for NLR and a specificity of 92.3% for CA199. HE4 emerged as the most reliable predictor, demonstrating a specificity of 84.6% and a sensitivity of 75.3%. The area under the curve of the combined CA125 and HE4 assays for predicting the ineffectiveness of NACT in individuals facing advanced ovarian cancer was 0.825, showcasing a specificity of 74.2% and a sensitivity of 84.6%.
UNASSIGNED: The predictive capacity for the effectiveness of NACT in individuals facing advanced ovarian cancer is notably high when considering the sensitivity of NLR and the specificity of CA199. Additionally, the combination of CA125 and HE4 assays can obtain a better predictive effect, which can accurately select patients suitable for NACT, determine the appropriate timing of the interval debulking surgery (IDS) surgery, and achieve a satisfactory tumor reduction effect.
摘要：
■本研究旨在评估各种生物标志物的临床重要性，包括NLR,CEA,CA199，CA125，CA153和HE4，通过动态测试来评估新辅助化疗（NACT）对晚期卵巢癌患者的有效性。这为针对个体患者定制治疗计划提供了有价值的信息，从而导致面临卵巢癌的个体的更个性化和有效的管理。
■NLR的水平，CA125,CA199,CEA,分别于化疗前和化疗3个疗程后检测CA153、HE4。根据NACT的有效性将患者分为无效组和有效组。评价NACT对晚期卵巢癌患者疗效的影响因素,接收机工作特性(ROC)曲线，预测建模，并采用多因素回归分析。
■在有效组中，病人的年龄，肿瘤最大直径,与无效组相比，患者的CEA和HE4水平明显高于无效组（P<0.05）。此外,有效组与无效组治疗前后HE4水平差异有统计学意义(P<0.05)。多因素分析显示，年龄和最大肿瘤直径是影响晚期卵巢癌患者NACT疗效的独立危险因素（P<0.05）。预测NACT在晚期卵巢癌患者中的有效性的ROC曲线显示，NLR的敏感性为93.3%，CA199的特异性为92.3%。HE4成为最可靠的预测因子，特异性为84.6%，灵敏度为75.3%。CA125和HE4联合检测预测晚期卵巢癌患者NACT无效的曲线下面积为0.825，特异性为74.2%，灵敏度为84.6%。
■当考虑NLR的敏感性和CA199的特异性时，NACT在面临晚期卵巢癌的个体中的有效性的预测能力非常高。此外,CA125和HE4联合检测可以获得更好的预测效果,可以准确选择适合NACT的患者，确定间隔减积手术（IDS）手术的适当时机，取得满意的肿瘤缩小效果。
■NLR的水平，CA125,CA199,CEA,分别于化疗前和化疗3个疗程后检测CA153、HE4。根据NACT的有效性将患者分为无效组和有效组。评价NACT对晚期卵巢癌患者疗效的影响因素,接收机工作特性(ROC)曲线，预测建模，并采用多因素回归分析。
■在有效组中，病人的年龄，肿瘤最大直径,与无效组相比，患者的CEA和HE4水平明显高于无效组（P<0.05）。此外,有效组与无效组治疗前后HE4水平差异有统计学意义(P<0.05)。多因素分析显示，年龄和最大肿瘤直径是影响晚期卵巢癌患者NACT疗效的独立危险因素（P<0.05）。预测NACT在晚期卵巢癌患者中的有效性的ROC曲线显示，NLR的敏感性为93.3%，CA199的特异性为92.3%。HE4成为最可靠的预测因子，特异性为84.6%，灵敏度为75.3%。CA125和HE4联合检测预测晚期卵巢癌患者NACT无效的曲线下面积为0.825，特异性为74.2%，灵敏度为84.6%。
■当考虑NLR的敏感性和CA199的特异性时，NACT在面临晚期卵巢癌的个体中的有效性的预测能力非常高。此外,CA125和HE4联合检测可以获得更好的预测效果,可以准确选择适合NACT的患者，确定间隔减积手术（IDS）手术的适当时机，取得满意的肿瘤缩小效果。
